Oric Pharmaceuticals (ORIC) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to Oric Pharmaceuticals (ORIC) yesterday and set a price target of $52.00. The company’s shares closed last Tuesday at $24.08.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 57.0% and a 58.9% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Sensei Biotherapeutics, and Cellectar Biosciences.

Oric Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $43.00.

See today’s analyst top recommended stocks >>

Oric Pharmaceuticals’ market cap is currently $915.1M and has a P/E ratio of -12.60. The company has a Price to Book ratio of 5.11.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts